What's in PepTcell Limited's pipeline?

PepTcell Limited has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with PepTcell Limited's portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, Merck Sharp & Dohme LLC, Sanofi Pasteur, a Sanofi Company, Seqirus, Sinovac Biotech Co., Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/peptcell-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

PepTcell Limited — Portfolio Competitive Intelligence Brief

PepTcell Limited pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Infectious Diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Sanofi Pasteur, a Sanofi Company · 1 shared drug class
Seqirus · 1 shared drug class
Sinovac Biotech Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PepTcell Limited:

Cite this brief

Drug Landscape (2026). PepTcell Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/peptcell-limited. Accessed 2026-05-14.